162 related articles for article (PubMed ID: 37350233)
21. A Retrospective Observational Study of Factors Affecting the Efficacy of Concurrent Prescription of Naldemedine for Opioid-Induced Constipation Caused by Oxycodone Tablets.
Yamada M; Jimaru Y; Torii S; Mitsuba N; Takahashi K
Biol Pharm Bull; 2023; 46(12):1826-1831. PubMed ID: 38044102
[TBL] [Abstract][Full Text] [Related]
22. Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.
Streicher JM; Bilsky EJ
J Pharm Pract; 2018 Dec; 31(6):658-669. PubMed ID: 28946783
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Naldemedine Administration for Opioid-Induced Constipation in Cancer Patients with Poor Performance Status.
Fujita Y; Imai H; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
J Palliat Med; 2023 Apr; 26(4):548-553. PubMed ID: 36971576
[No Abstract] [Full Text] [Related]
24. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.
Takagi Y; Osawa G; Kato Y; Ikezawa E; Kobayashi C; Aruga E
BMC Gastroenterol; 2020 Jan; 20(1):25. PubMed ID: 32005157
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis.
Nee J; Zakari M; Sugarman MA; Whelan J; Hirsch W; Sultan S; Ballou S; Iturrino J; Lembo A
Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1569-1584.e2. PubMed ID: 29374616
[TBL] [Abstract][Full Text] [Related]
26. Naldemedine for the Use of Management of Opioid Induced Constipation.
Urits I; Patel A; Kiernan HC; Clay CJ; Monteferrante N; Jung JW; Berger AA; Kassem H; Hasoon J; Kaye AD; Kaye AM; Viswanath O
Psychopharmacol Bull; 2020 Jul; 50(3):97-118. PubMed ID: 32733114
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of naldemedine for opioid-induced constipation in older patients with cancer: a retrospective study.
Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
Eur J Gastroenterol Hepatol; 2024 May; 36(5):571-577. PubMed ID: 38477855
[TBL] [Abstract][Full Text] [Related]
28. A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients.
Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Kaira K; Minato K
Thorac Cancer; 2022 Aug; 13(16):2301-2308. PubMed ID: 35790500
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
Wild J; Webster L; Yamada T; Hale M
Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
[TBL] [Abstract][Full Text] [Related]
30. Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan.
Takata K; Nakazawa M; Honda K; Hashimoto S
Support Care Cancer; 2022 May; 30(5):3943-3954. PubMed ID: 35044484
[TBL] [Abstract][Full Text] [Related]
31. Factors affecting the effect of naldemedine for opioid-induced constipation: a single-institution, retrospective analysis.
Kanbayashi Y; Amaya F; Ueno H; Tabuchi Y; Ishikawa T; Takayama K; Taguchi T
Pharmazie; 2021 Apr; 76(4):175-178. PubMed ID: 33849704
[TBL] [Abstract][Full Text] [Related]
32. Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.
De Giorgio R; Zucco FM; Chiarioni G; Mercadante S; Corazziari ES; Caraceni A; Odetti P; Giusti R; Marinangeli F; Pinto C
Adv Ther; 2021 Jul; 38(7):3589-3621. PubMed ID: 34086265
[TBL] [Abstract][Full Text] [Related]
33. Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study.
Hiruta E; Fujita Y; Imai H; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Nishiba H; Mogi J; Kotake M; Koizuka S; Minato K
Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833451
[No Abstract] [Full Text] [Related]
34. Naldemedine for opioid-induced constipation.
Drug Ther Bull; 2022 Mar; 60(3):39-43. PubMed ID: 35197302
[No Abstract] [Full Text] [Related]
35. A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting.
Sato J; Tanaka R; Ishikawa H; Suzuki T; Shino M
Support Care Cancer; 2020 Mar; 28(3):1083-1088. PubMed ID: 31183560
[TBL] [Abstract][Full Text] [Related]
36. Treatment of opioid-induced constipation: focus on the peripheral μ-opioid receptor antagonist methylnaltrexone.
Rauck RL
Drugs; 2013 Aug; 73(12):1297-306. PubMed ID: 23881667
[TBL] [Abstract][Full Text] [Related]
37. Naldemedine is associated with earlier defecation in critically ill patients with opioid-induced constipation: A retrospective, single-center cohort study.
Nishiyama S; Uchino S; Sasabuchi Y; Masuyama T; Lefor AK; Sanui M
PLoS One; 2024; 19(1):e0295952. PubMed ID: 38170714
[TBL] [Abstract][Full Text] [Related]
38. Use of naldemedine is associated with reduced incidence of hyperactive delirium in cancer patients with opioid-induced constipation: A nationwide retrospective cohort study in Japan.
Abe H; Sumitani M; Matsui H; Inoue R; Fushimi K; Uchida K; Yasunaga H
Pharmacotherapy; 2022 Mar; 42(3):241-249. PubMed ID: 34967450
[TBL] [Abstract][Full Text] [Related]
39. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review.
Leppert W
Adv Ther; 2010 Oct; 27(10):714-30. PubMed ID: 20799006
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic effects of naldemedine, a peripherally acting μ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation.
Kanemasa T; Koike K; Arai T; Ono H; Horita N; Chiba H; Nakamura A; Morioka Y; Kihara T; Hasegawa M
Neurogastroenterol Motil; 2019 May; 31(5):e13563. PubMed ID: 30821019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]